acetaminophen has been researched along with Common Cold in 52 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Common Cold: A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A fixed-dose combination of paracetamol, chlorphenamine and phenylephrine was safe and more effective than placebo in the symptomatic treatment of the common cold or flu-like syndrome in adults." | 9.17 | Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial. ( Costa, MB; da Veiga Picon, R; Dornelles, AD; Fendt, LC; Picon, PD; Saccilotto, IC; Schmidt, LF; Suksteris, ML, 2013) |
| "The results confirm the multisymptom benefit of a single dose of the test syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate and support its role as an effective and convenient therapy for symptoms of nasal congestion, runny nose, cough and pain/body aches associated with the common cold and for increasing sleep quality disturbed by the common cold." | 9.12 | Efficacy of a single evening dose of syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. ( Goodale, M; Grender, JM; Hull, JD; Jerdack, GR; Mizoguchi, H; Tyler, BA; Wilson, A, 2007) |
| "It was the aim of this clinical study to demonstrate the efficacy of 1000 mg acetylsalicylic acid (ASA, CAS 50-78-2) in combination with 60 mg pseudoephedrine (PSE, CAS 90-82-4), compared with placebo, in the symptomatic treatment of nasal congestion associated with the common cold." | 9.11 | Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. ( Loose, I; Winkel, M, 2004) |
| "2 g daily), aspirin and paracetamol (both up to 3 g daily) for up to seven days, in patients with mild to moderate pain resulting from cold/flu symptoms or sore throat (CF/ST) (n = 2,815)." | 9.10 | Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. ( Cairns, R; Le Parc, JM; Moore, N; Schneid, H; van Ganse, E; Wall, R, 2002) |
| "Acetaminophen is frequently prescribed for treating patients with the common cold, but there is little evidence as to whether it is effective." | 8.89 | Acetaminophen (paracetamol) for the common cold in adults. ( Dong, BR; Li, S; Lin, X; Wu, T; Yang, M; Yue, J, 2013) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 8.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 8.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| " Eligible participants with at least moderate common cold or flu symptoms and symptom onset ≤ 48 hours before screening were assigned to a single multiple-active-ingredient tablet (containing paracetamol, pseudoephedrine hydrochloride, dextromethorphan hydrobromide, and chlorpheniramine maleate) or placebo tablet." | 5.27 | Time-to-onset of cold and flu symptom relief: A randomized, double-blind, placebo-controlled pilot study for a multi-symptom combination product. ( Mallefet, P; Zhang, Y, 2018) |
| "A fixed-dose combination of paracetamol, chlorphenamine and phenylephrine was safe and more effective than placebo in the symptomatic treatment of the common cold or flu-like syndrome in adults." | 5.17 | Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial. ( Costa, MB; da Veiga Picon, R; Dornelles, AD; Fendt, LC; Picon, PD; Saccilotto, IC; Schmidt, LF; Suksteris, ML, 2013) |
| "The results confirm the multisymptom benefit of a single dose of the test syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate and support its role as an effective and convenient therapy for symptoms of nasal congestion, runny nose, cough and pain/body aches associated with the common cold and for increasing sleep quality disturbed by the common cold." | 5.12 | Efficacy of a single evening dose of syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms. ( Goodale, M; Grender, JM; Hull, JD; Jerdack, GR; Mizoguchi, H; Tyler, BA; Wilson, A, 2007) |
| "It was the aim of this clinical study to demonstrate the efficacy of 1000 mg acetylsalicylic acid (ASA, CAS 50-78-2) in combination with 60 mg pseudoephedrine (PSE, CAS 90-82-4), compared with placebo, in the symptomatic treatment of nasal congestion associated with the common cold." | 5.11 | Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold. ( Loose, I; Winkel, M, 2004) |
| "2 g daily), aspirin and paracetamol (both up to 3 g daily) for up to seven days, in patients with mild to moderate pain resulting from cold/flu symptoms or sore throat (CF/ST) (n = 2,815)." | 5.10 | Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. ( Cairns, R; Le Parc, JM; Moore, N; Schneid, H; van Ganse, E; Wall, R, 2002) |
| "A prospective, randomized, double-blind, multicenter, 4-arm, controlled trial was carried out in 1,167 patients with common cold treated with one of the following medications: Grippostad-C, a combination of acetaminophen, caffeine, chlorpheniramine and ascorbic acid (verum), ascorbic acid (control), chlorpheniramine and ascorbic acid (reference 1), as well as acetaminophen, caffeine, and ascorbic acid (reference 2)." | 5.10 | Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. ( Alken, RG; Bacratcheva, N; Gawronska-Szklarz, B; Giesel, B; Koytchev, R; Mrozikiewiczs, A; van der Meer, M; Vlahov, V; Wojcicki, J, 2003) |
| "Acetaminophen is frequently prescribed for treating patients with the common cold, but there is little evidence as to whether it is effective." | 4.89 | Acetaminophen (paracetamol) for the common cold in adults. ( Dong, BR; Li, S; Lin, X; Wu, T; Yang, M; Yue, J, 2013) |
| "To analyse major sources of evidence-based information on the efficacy and gastrointestinal tolerability of aspirin, used short-term, in over-the-counter (OTC) doses, to relieve acute pain and cold symptoms, including associated feverishness." | 4.88 | Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. ( McCarthy, DM, 2012) |
| "Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited." | 4.87 | Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. ( Baron, JA; Brueckner, A; Lanas, A; McCarthy, D; Senn, S; Voelker, M, 2011) |
| "A combination of paracetamol, pseudoephedrine, chlorpheniramine, and sodium benzoate in (Cold-Flu) 1,2,3 Syrup dosage form is specified for the treatment of common cold and flu symptoms." | 4.12 | Stability-Indicating New RP-UPLC Method for Simultaneous Determination of a Quaternary Mixture of Paracetamol, Pseudoephedrine, Chlorpheniramine, and Sodium Benzoate in (Cold-Flu) Syrup Dosage Form. ( Mohamed, MA, 2022) |
| "Different pharmaceutical preparations against the common cold contain acetaminophen, phenylephrine hydrochloride, and chlorpheniramine maleate." | 3.73 | Major degradation product identified in several pharmaceutical formulations against the common cold. ( Al-Mamoon, S; Chan, TM; Cooper, T; Wiseman, L; Wong, J; Zhang, LK, 2006) |
| " One of the sisters experienced a common cold before the pemphigus developed and displayed a positive macrophage migration inhibition (MIF) test to a combination drug compounded of paracetamol, caffeine, chlorpheniramine maleate and phenylephrine HCl, which she had received 2 weeks prior to the appearance of the cutaneous lesions." | 3.68 | A possible case of drug-induced familial pemphigus. ( Brenner, S; Dascalu, D; Hodak, E; Lurie, R; Wolf, R, 1990) |
| "Common cold symptoms may be mitigated by products in caplet, nasal spray, and oral solution formulations, although variations exist in the bioavailability of the active ingredients contained within these products." | 3.11 | A single-dose, open-label, randomized, scintigraphic study to investigate the gastrointestinal behavior of 2 triple-combination cold products (acetaminophen, phenylephrine, and dextromethorphan) in healthy male volunteers. ( Armogida, M; Doll, WJ; Mallefet, P; Page, RC; Sandefer, EP, 2022) |
| "The developed methods are successfully applied for concurrent quantification of the studied components in the marketed dosage form without interference from matrix excipients." | 2.82 | Novel Spectrophotometric Approaches for the Simultaneous Quantification of Ternary Common Cold Mixture Containing Paracetamol with a Challenging Formulation Ratio: Greenness Profile Evaluation. ( Fayez, YM; Monir, HH; Mostafa, NM; Rostom, Y; Soliman, RM, 2022) |
| "Common colds are usually treated by the patients themselves with over-the-counter (OTC) cold medications." | 2.71 | Treatment of the common cold. ( Cutchavaree, A; Kerekhanjananarong, V; Saengpanich, S; Supiyaphun, P, 2003) |
| "Despite the lack of clinical data on the safety and efficacy of analgesics for the treatment of colds and flu symptoms a case can be made that these medicines are safe and effective for treatment of these common illnesses." | 2.43 | Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu. ( Eccles, R, 2006) |
| " The advantages of the proposed method qualify it for routine analysis of the studied drugs either in single or co-formulated dosage form in quality control labs." | 1.91 | A quality-by-design eco-friendly UV-HPLC method for the determination of four drugs used to treat symptoms of common cold and COVID-19. ( Abdallah, NA; El-Brashy, AM; Fathy, ME; Ibrahim, FA; Tolba, MM, 2023) |
| " Pharmacists should warn users to follow labelled dosing directions, especially during CFS." | 1.48 | Prevalence of exceeding maximum daily dose of paracetamol, and seasonal variations in cold-flu season. ( Battista, DR; Kaufman, DW; Kelly, JP; Malone, MK; Shiffman, S; Weinstein, RB, 2018) |
| "Acetaminophen was detected in blood from each of the five cases with sufficient sample." | 1.34 | Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children. ( Chmara, ES; Collins, GL; Mundy, LA; Wingert, WE, 2007) |
| "We report a case of toxic epidermal necrolysis-type drug eruption." | 1.31 | A case of toxic epidermal necrolysis-type drug eruption induced by oral lysozyme chloride. ( Asahi, M; Kobayashi, M; Yamamoto, O; Yasuda, H, 2000) |
| "We report a case of eosinophilic pneumonia induced by Pelex granule." | 1.31 | [A case of eosinophilic pneumonia induced by Pelex granule]. ( Hiramatsu, K; Kudo, K; Suzuki, T; Takeda, Y; Yamauchi, Y, 2002) |
| "The incidence of Reye syndrome has been decreasing in Michigan, perhaps as a result of decreased aspirin use among children." | 1.27 | Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984. ( Hall, WN; McGee, H; Monto, AS; Remington, PL; Rowley, D, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (21.15) | 18.7374 |
| 1990's | 3 (5.77) | 18.2507 |
| 2000's | 21 (40.38) | 29.6817 |
| 2010's | 12 (23.08) | 24.3611 |
| 2020's | 5 (9.62) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, MA | 1 |
| Mallefet, P | 2 |
| Armogida, M | 1 |
| Doll, WJ | 1 |
| Page, RC | 1 |
| Sandefer, EP | 1 |
| Soliman, RM | 1 |
| Mostafa, NM | 1 |
| Fayez, YM | 1 |
| Monir, HH | 1 |
| Rostom, Y | 1 |
| Abdallah, NA | 1 |
| Fathy, ME | 1 |
| Tolba, MM | 1 |
| El-Brashy, AM | 1 |
| Ibrahim, FA | 1 |
| Paudel, S | 1 |
| Aryal, B | 1 |
| Komagamine, J | 1 |
| Shiffman, S | 1 |
| Battista, DR | 1 |
| Kelly, JP | 1 |
| Malone, MK | 1 |
| Weinstein, RB | 1 |
| Kaufman, DW | 1 |
| Zhang, Y | 1 |
| Li, S | 1 |
| Yue, J | 1 |
| Dong, BR | 1 |
| Yang, M | 1 |
| Lin, X | 1 |
| Wu, T | 1 |
| Picon, PD | 1 |
| Costa, MB | 1 |
| da Veiga Picon, R | 1 |
| Fendt, LC | 1 |
| Suksteris, ML | 1 |
| Saccilotto, IC | 1 |
| Dornelles, AD | 1 |
| Schmidt, LF | 1 |
| Allan, GM | 1 |
| Arroll, B | 1 |
| Okabayashi, S | 1 |
| Goto, M | 1 |
| Kawamura, T | 1 |
| Watanabe, H | 1 |
| Kimura, A | 1 |
| Uruma, R | 1 |
| Takahashi, Y | 1 |
| Taneichi, S | 1 |
| Musashi, M | 1 |
| Miyaki, K | 1 |
| Danno, K | 1 |
| Cognet-Dementhon, B | 1 |
| Thevenard, G | 1 |
| Duru, G | 1 |
| Allaert, FA | 1 |
| Bordet, MF | 1 |
| Liu, X | 2 |
| Zhang, J | 1 |
| Chen, X | 2 |
| Pourahmad, M | 1 |
| Sobhanian, S | 1 |
| López Abad, R | 1 |
| Iriarte Sotés, P | 1 |
| Castro Murga, M | 1 |
| Gracia Bara, MT | 1 |
| Sesma Sánchez, P | 1 |
| Lanas, A | 1 |
| McCarthy, D | 1 |
| Voelker, M | 1 |
| Brueckner, A | 1 |
| Senn, S | 1 |
| Baron, JA | 1 |
| McCarthy, DM | 1 |
| Moore, N | 1 |
| Le Parc, JM | 1 |
| van Ganse, E | 1 |
| Wall, R | 1 |
| Schneid, H | 1 |
| Cairns, R | 1 |
| Koytchev, R | 1 |
| Vlahov, V | 1 |
| Bacratcheva, N | 1 |
| Giesel, B | 1 |
| Gawronska-Szklarz, B | 1 |
| Wojcicki, J | 1 |
| Mrozikiewiczs, A | 1 |
| van der Meer, M | 1 |
| Alken, RG | 1 |
| Supiyaphun, P | 1 |
| Kerekhanjananarong, V | 1 |
| Saengpanich, S | 1 |
| Cutchavaree, A | 1 |
| KOVALEFF, MO | 1 |
| MANSON, MH | 1 |
| WELLS, RL | 1 |
| WHITNEY, LH | 1 |
| BABCOCK, G | 1 |
| Mao, YQ | 1 |
| Mu, ZX | 1 |
| Zhang, YF | 1 |
| Loose, I | 1 |
| Winkel, M | 1 |
| Eccles, R | 1 |
| Wong, J | 1 |
| Wiseman, L | 1 |
| Al-Mamoon, S | 1 |
| Cooper, T | 1 |
| Zhang, LK | 1 |
| Chan, TM | 1 |
| Wingert, WE | 1 |
| Mundy, LA | 1 |
| Collins, GL | 1 |
| Chmara, ES | 1 |
| Liu, L | 1 |
| Chen, H | 1 |
| Hasemann, P | 1 |
| ter Balk, M | 1 |
| Preu, L | 1 |
| Wätzig, H | 1 |
| Mizoguchi, H | 1 |
| Wilson, A | 1 |
| Jerdack, GR | 1 |
| Hull, JD | 1 |
| Goodale, M | 1 |
| Grender, JM | 1 |
| Tyler, BA | 1 |
| Lea, P | 1 |
| Middleton, RS | 1 |
| Flannery, DB | 1 |
| Kobayashi, M | 1 |
| Yamamoto, O | 1 |
| Yasuda, H | 1 |
| Asahi, M | 1 |
| Suntornsuk, L | 1 |
| Karch, AM | 1 |
| Karch, FE | 1 |
| Hiramatsu, K | 1 |
| Takeda, Y | 1 |
| Yamauchi, Y | 1 |
| Suzuki, T | 1 |
| Kudo, K | 1 |
| Cardona, I | 1 |
| Grau, S | 1 |
| Marín, M | 1 |
| Thackray, P | 1 |
| Gorske, AL | 1 |
| Brenner, S | 1 |
| Hodak, E | 1 |
| Dascalu, D | 1 |
| Lurie, R | 1 |
| Wolf, R | 1 |
| Graham, NM | 1 |
| Burrell, CJ | 1 |
| Douglas, RM | 1 |
| Debelle, P | 1 |
| Davies, L | 1 |
| Nishi, H | 1 |
| Fukuyama, T | 1 |
| Matsuo, M | 1 |
| Terabe, S | 1 |
| Remington, PL | 1 |
| Rowley, D | 1 |
| McGee, H | 1 |
| Hall, WN | 1 |
| Monto, AS | 1 |
| Peter, M | 1 |
| Froidevaux, T | 1 |
| Felber, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Dose, Open Label, Randomized Scintigraphic Study to Investigate the Gastrointestinal Behavior of 2 Triple Combination Products (Acetaminophen, Phenylephrine and Dextromethorphan) in Healthy Male Volunteers[NCT03415243] | Phase 1 | 28 participants (Actual) | Interventional | 2018-03-01 | Completed | ||
| Phase III Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold[NCT02735070] | Phase 3 | 366 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | ||
| Evaluation of the Efficacy and Safety of Fixed Combination of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Symptomatic Common Cold and Flu Syndrome in Adults[NCT01389518] | Phase 3 | 146 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area under the gastric emptying curve from time 0 to 105 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 105 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 105 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 53.16 |
| Treatment Group B | 31.81 |
Area under the gastric emptying curve from time 0 to 120 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 120 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 120 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 54.49 |
| Treatment Group B | 32.15 |
Area under the gastric emptying curve from time 0 to 15 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 15 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 15 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 19.38 |
| Treatment Group B | 16.96 |
Area under the gastric emptying curve from time 0 to 180 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 180 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 180 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 56.69 |
| Treatment Group B | 32.61 |
Area under the gastric emptying curve from time 0 to 240 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 240 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 240 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 56.80 |
| Treatment Group B | 32.61 |
Area under the gastric emptying curve from time 0 to 30 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 30 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 30 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 31.16 |
| Treatment Group B | 25.11 |
Area under the gastric emptying curve from time 0 to 45 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 45 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 45 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 38.36 |
| Treatment Group B | 28.19 |
Area under the gastric emptying curve from time 0 to 60 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 60 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 60 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 43.69 |
| Treatment Group B | 29.60 |
Area under the gastric emptying curve from time 0 to 75 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 75 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 75 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 48.71 |
| Treatment Group B | 30.61 |
Area under the gastric emptying curve from time 0 to 90 was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 90 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 90 minutes post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 51.32 |
| Treatment Group B | 31.29 |
Gastric emptying half-life was defined as the time required by the stomach to empty 50% of the ingested meal and was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA). Data images were analyzed in a time-lapse format and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | minutes (Median) |
|---|---|
| Treatment Group A | 25.00 |
| Treatment Group B | 5.00 |
Mean time to gastric emptying by 25 percent (GE25%) was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA). Data images were analyzed in a time-lapse format and corrected for radioactive decay and background radiation. ROI included the stomach, proximal small intestine, distal small intestine and colon. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | minutes (Mean) |
|---|---|
| Treatment Group A | 12.614 |
| Treatment Group B | 12.171 |
Mean time to gastric emptying by 50 percent (GE50%) was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA). Data images were analyzed in a time-lapse format and corrected for radioactive decay and background radiation. ROI included the stomach, proximal small intestine, distal small intestine and colon. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | minutes (Mean) |
|---|---|
| Treatment Group A | 22.643 |
| Treatment Group B | 16.134 |
Mean time to gastric emptying by 90 percent (GE90%) was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA). Data images were analyzed in a time-lapse format and corrected for radioactive decay and background radiation. ROI included the stomach, proximal small intestine, distal small intestine and colon. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | minutes (Mean) |
|---|---|
| Treatment Group A | 84.929 |
| Treatment Group B | 36.214 |
Mean time to complete gastric emptying in participants who did not vomit shortly (within 60 minutes) after study drug administration was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m-DTPA). Data images were analyzed in a time-lapse format and corrected for radioactive decay and background radiation. ROI included the stomach, proximal small intestine, distal small intestine and colon. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | minutes (Mean) |
|---|---|
| Treatment Group A | 121.2 |
| Treatment Group B | 65.3 |
Mean time to onset of gastric emptying in participants who did not vomit shortly (within 60 minutes) after study drug administration was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 microcurie [mcCi] isotope-technetium-99m-diethylene-triamine-pentaacetate [DTPA]). Data images were analyzed in a time-lapse format and corrected for radioactive decay and background radiation. Regions of interest (ROI) included the stomach, proximal small intestine, distal small intestine and colon. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | minutes (Mean) |
|---|---|
| Treatment Group A | 1.107 |
| Treatment Group B | 8.534 |
Haematological, biochemistry, urinalysis and virological parameters were analyzed. Clinical significance was judged by the investigator based upon the out of range values of standard range set for each parameter. (NCT03415243)
Timeframe: From baseline up to Day 1
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Group A | 0 |
| Treatment Group B | 0 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 105 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 105 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 6.06 |
| Treatment Group B | 1.72 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 120 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 120 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 4.34 |
| Treatment Group B | 0.99 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 15 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 15 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 67.00 |
| Treatment Group B | 49.77 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 180 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 180 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 0.64 |
| Treatment Group B | 0.00 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 240 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 240 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 0.00 |
| Treatment Group B | 0.00 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 30 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 30 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 33.24 |
| Treatment Group B | 20.87 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 45 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 45 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 24.79 |
| Treatment Group B | 7.21 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 60 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 60 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 20.07 |
| Treatment Group B | 4.26 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 75 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 75 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 14.73 |
| Treatment Group B | 3.28 |
Percentage of radiolabeled drug remaining in the stomach was evaluated by scintigraphic imaging, performed immediately after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA) and after 90 minutes of drug ingestion. Data images were analyzed and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: 90 minutes post dose on Day 1
| Intervention | percentage of radiolabeled drug (Mean) |
|---|---|
| Treatment Group A | 8.84 |
| Treatment Group B | 2.45 |
Small intestinal transit time was calculated by determining the arrival time of the radiolabeled investigational drug formulation at the cecum or colon region from scintigraphic imaging and subtracting the gastric emptying value. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | minutes (Median) |
|---|---|
| Treatment Group A | 184.0 |
| Treatment Group B | 139.5 |
Total area under the gastric emptying curve was evaluated by scintigraphic imaging, performed after ingestion of the investigational drug formulation (radiolabeled with not more than 108 mcCi isotope-technetium-99m DTPA). Data images were analyzed in a time-lapse format and corrected for radioactive decay and background radiation. (NCT03415243)
Timeframe: Predose until 10 hours post dose on Day 1
| Intervention | percentage dose*hour (Mean) |
|---|---|
| Treatment Group A | 56.80 |
| Treatment Group B | 32.61 |
6 reviews available for acetaminophen and Common Cold
| Article | Year |
|---|---|
Novel Spectrophotometric Approaches for the Simultaneous Quantification of Ternary Common Cold Mixture Containing Paracetamol with a Challenging Formulation Ratio: Greenness Profile Evaluation.
Topics: Acetaminophen; Common Cold; Cough; COVID-19; Humans; Pseudoephedrine; Spectrophotometry | 2022 |
Acetaminophen (paracetamol) for the common cold in adults.
Topics: Acetaminophen; Adult; Common Cold; Humans; Nasal Obstruction; Randomized Controlled Trials as Topic; | 2013 |
Prevention and treatment of the common cold: making sense of the evidence.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antitussive Agents | 2014 |
Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinal adverse effects: a meta-analysis of randomized clinical trials.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Common Cold; Double-Blind Me | 2011 |
Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold.
Topics: Acetaminophen; Aspirin; Common Cold; Dyspepsia; Fever; Gastrointestinal Tract; Humans; Ibuprofen; No | 2012 |
Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Com | 2006 |
14 trials available for acetaminophen and Common Cold
| Article | Year |
|---|---|
A single-dose, open-label, randomized, scintigraphic study to investigate the gastrointestinal behavior of 2 triple-combination cold products (acetaminophen, phenylephrine, and dextromethorphan) in healthy male volunteers.
Topics: Acetaminophen; Adult; Common Cold; Cross-Over Studies; Dextromethorphan; Healthy Volunteers; Humans; | 2022 |
Time-to-onset of cold and flu symptom relief: A randomized, double-blind, placebo-controlled pilot study for a multi-symptom combination product.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Antitussive Agents; China; Chl | 2018 |
Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial.
Topics: Acetaminophen; Adolescent; Adult; Chlorpheniramine; Common Cold; Double-Blind Method; Drug Combinati | 2013 |
Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial.
Topics: Acetaminophen; Adolescent; Adult; Chlorpheniramine; Common Cold; Double-Blind Method; Drug Combinati | 2013 |
Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial.
Topics: Acetaminophen; Adolescent; Adult; Chlorpheniramine; Common Cold; Double-Blind Method; Drug Combinati | 2013 |
Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial.
Topics: Acetaminophen; Adolescent; Adult; Chlorpheniramine; Common Cold; Double-Blind Method; Drug Combinati | 2013 |
Non-superiority of Kakkonto, a Japanese herbal medicine, to a representative multiple cold medicine with respect to anti-aggravation effects on the common cold: a randomized controlled trial.
Topics: Acetaminophen; Adolescent; Adult; Aged; Codeine; Common Cold; Drug Combinations; Female; Follow-Up S | 2014 |
Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Co | 2002 |
Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Ascorbic Acid; Caffeine; Chlorphen | 2003 |
Treatment of the common cold.
Topics: Acetaminophen; Adolescent; Adult; Common Cold; Dextromethorphan; Doxylamine; Drug Combinations; Ephe | 2003 |
Clinical, double-blind, placebo-controlled study investigating the combination of acetylsalicylic acid and pseudoephedrine for the symptomatic treatment of nasal congestion associated with common cold.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Area Under | 2004 |
Efficacy of a single evening dose of syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple common cold symptoms.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Antitussive Agents; Bronchodilator Agent | 2007 |
A double-blind controlled evaluation of the nasal decongestant effect of Day Nurse in the common cold.
Topics: Acetaminophen; Adolescent; Adult; Aged; Ascorbic Acid; Codeine; Common Cold; Dextromethorphan; Doubl | 1984 |
Double blind trial in general practice comparing the efficacy of "Benylin Day and Night" and paracetamol in the treatment of the common cold.
Topics: Acetaminophen; Adolescent; Adult; Aged; Clinical Trials as Topic; Common Cold; Diphenhydramine; Doub | 1981 |
A double-blind, crossover controlled evaluation of a syrup for the night-time relief of the symptoms of the common cold, containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulphate.
Topics: Acetaminophen; Adolescent; Adult; Clinical Trials as Topic; Common Cold; Dextromethorphan; Double-Bl | 1978 |
Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers.
Topics: Acetaminophen; Adult; Antibodies, Viral; Aspirin; Common Cold; Double-Blind Method; Female; Fever; H | 1990 |
[Treatment of common cold with a new drug Co-Tylenol].
Topics: Acetaminophen; Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Common Co | 1972 |
32 other studies available for acetaminophen and Common Cold
| Article | Year |
|---|---|
Stability-Indicating New RP-UPLC Method for Simultaneous Determination of a Quaternary Mixture of Paracetamol, Pseudoephedrine, Chlorpheniramine, and Sodium Benzoate in (Cold-Flu) Syrup Dosage Form.
Topics: Acetaminophen; Chlorpheniramine; Chromatography, High Pressure Liquid; Common Cold; Humans; Pseudoep | 2022 |
A quality-by-design eco-friendly UV-HPLC method for the determination of four drugs used to treat symptoms of common cold and COVID-19.
Topics: Acetaminophen; Ambroxol; Chromatography, High Pressure Liquid; Common Cold; COVID-19; Humans; Phenyl | 2023 |
Exploration of self-medication practice in Pokhara valley of Nepal.
Topics: Acetaminophen; Adult; Analgesics; Anti-Bacterial Agents; Common Cold; Cough; Cross-Sectional Studies | 2020 |
Characteristics of the use of cold combination products among older ambulatory patients at the National Hospital Organization Tochigi Medical Center in Japan: a retrospective single-center observational study.
Topics: Acetaminophen; Aged; Aged, 80 and over; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; An | 2017 |
Prevalence of exceeding maximum daily dose of paracetamol, and seasonal variations in cold-flu season.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Common Cold; Dose-Response Relationship, Drug; Drug Dosage | 2018 |
[Study in general practice: healing the common cold: landing on the moon is easier].
Topics: Acetaminophen; Combined Modality Therapy; Common Cold; Drug Therapy, Combination; General Practice; | 2013 |
Your medicine cabinet's best cold fighter.
Topics: Acetaminophen; Common Cold; Drug Interactions; Humans; Ibuprofen | 2014 |
Management of the early symptoms of influenza-like illnesses and ear, nose and throat (ENT) disorders by pharmacists.
Topics: Acetaminophen; Adult; Common Cold; Cough; Disease Management; Early Diagnosis; Female; France; Homeo | 2014 |
Online concentration by head-column field-amplified with large-volume sample stacking using flow injection-capillary electrophoresis for the analysis of four active components in cold medicines.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Allergic Agents; Antitussive Agents; Chlorpheniramine; | 2008 |
Effect of honey on the common cold.
Topics: Acetaminophen; Adult; Chlorpheniramine; Common Cold; Female; Honey; Humans; Male; Naproxen; Treatmen | 2009 |
Fixed drug eruption induced by phenylephrine: a case of polysensitivity.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Bronchial Provocation Tests; Common Cold; Cross Reac | 2009 |
Best drugs for what ails you: the brands to buy--and those to skip.
Topics: Acetaminophen; Anesthetics, Local; Cetirizine; Chlorpheniramine; Common Cold; Cough; Dextromethorpha | 2009 |
A study of coricidin in the treatment of the common cold.
Topics: Acetaminophen; Chlorpheniramine; Common Cold; Histamine Antagonists | 1950 |
Coricidin in the treatment of the common cold.
Topics: Acetaminophen; Chlorpheniramine; Common Cold; Histamine H1 Antagonists; Humans; Pheniramine | 1951 |
[Experimental study on the pharmacology of 999 ganmaoling, a compound recipe of Chinese and Western materia medica].
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Chlorpheniramine; Common | 2004 |
Are any cold medications safe for a person on high blood pressure medication?
Topics: Acetaminophen; Chlorpheniramine; Common Cold; Dextromethorphan; Drug Combinations; Drug Interactions | 2006 |
Major degradation product identified in several pharmaceutical formulations against the common cold.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Allergic Agents; Chemistry, Pharmaceutical; Chlorpheni | 2006 |
Possible role of pseudoephedrine and other over-the-counter cold medications in the deaths of very young children.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Antitussive Agents; Brompheniramine; Bronchodil | 2007 |
Separation and determination of four active components in medicinal preparations by flow injection-capillary electrophoresis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antitussive Agents; Bronchodilator Agents; Buffers; Chlorph | 2007 |
Separation of cold medicine ingredients using a precise MEKC method at elevated pH.
Topics: Acetaminophen; Buffers; Chromatography, Micellar Electrokinetic Capillary; Common Cold; Dextromethor | 2007 |
Parent's knowledge about acetaminophen.
Topics: Acetaminophen; Child, Preschool; Common Cold; Female; Humans; Parents | 1981 |
A case of toxic epidermal necrolysis-type drug eruption induced by oral lysozyme chloride.
Topics: Acetaminophen; Administration, Oral; Adult; Anti-Inflammatory Agents; Betamethasone; Biopsy, Needle; | 2000 |
Separation of cold medicine ingredients by capillary electrophoresis.
Topics: Acetaminophen; Buffers; Chlorpheniramine; Chromatography, Micellar Electrokinetic Capillary; Common | 2001 |
Let the user beware. OTC drugs aren't necessarily 'safe when taken as directed.'.
Topics: Acetaminophen; Adult; Common Cold; Diphenhydramine; Drug Combinations; Drug Overdose; Female; Humans | 2001 |
[A case of eosinophilic pneumonia induced by Pelex granule].
Topics: Acetaminophen; Adult; Common Cold; Humans; Male; Pulmonary Eosinophilia; Salicylates | 2002 |
[Sudden death attributed to ventricular arrhytmia induced by an over-the-counter drug for influenza].
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Arrhythmias, Cardiac; Chlorpheniramine; Common Cold; | 2002 |
Let's stop prescribing cold medications.
Topics: Acetaminophen; Aspirin; Common Cold; Drug Prescriptions; Humans | 1976 |
A possible case of drug-induced familial pemphigus.
Topics: Acetaminophen; Caffeine; Chlorpheniramine; Common Cold; Drug Combinations; Female; Humans; Middle Ag | 1990 |
Separation and determination of the ingredients of a cold medicine by micellar electrokinetic chromatography with bile salts.
Topics: Acetaminophen; Bile Acids and Salts; Caffeine; Chlorpheniramine; Chromatography; Common Cold; Hydrog | 1990 |
Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984.
Topics: Acetaminophen; Aspirin; Child; Common Cold; Fever; Humans; Michigan; Reye Syndrome | 1986 |
[The therapy of rhinitis and cold syndromes].
Topics: Acetaminophen; Common Cold; Humans; Phenylephrine; Rhinitis | 1972 |
[New combined therapy in influenza and common cold with Theraflu].
Topics: Acetaminophen; Adult; Caffeine; Child; Codeine; Common Cold; Female; Flavonoids; Humans; Influenza, | 1965 |